1-N-BOC-4-哌啶乙酸甲酯 | 175213-46-4

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-N-BOC-4-哌啶乙酸甲酯
• 中文别名: N-叔丁氧羰基-4-哌啶乙酸甲酯；N-Boc-4-哌啶乙酸甲酯；1-Boc-4-哌啶乙酸甲酯；叔丁基4-(2-甲氧基-2-氧代乙基)哌啶-1-甲酸叔丁酯
• 英文名称: tert-butyl 4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate
• 英文别名: 4-methoxycarbonylmethyl-piperidine-1-carboxylic acid tert-butyl ester；1-t-Butoxycarbonyl-4-(methoxycarbonylmethyl)piperidine
• CAS: 175213-46-4
• 化学式: C₁₃H₂₃NO₄
• mdl: MFCD01632529
• 分子量: 257.33
• InChiKey: ADFSCQGCEAKLOE-UHFFFAOYSA-N

物化性质

• 沸点：
  323.1±15.0 °C(Predicted)
• 密度：
  1.062±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.846
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl N-BOC-piperidine-4-acetate
Synonyms: t-Butyl 4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl N-BOC-piperidine-4-acetate
CAS number: 175213-46-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H23NO4
Molecular weight: 257.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-N-BOC-4-哌啶乙酸甲酯 在 carbonylhydrido(tetrahydroborato)[bis(2-diphenylphosphinoethyl)-amino]ruthenium(II) 、 氢气 、 sodium methylate 作用下， 以 甲醇 为溶剂， 100.0 ℃ 、5.07 MPa 条件下， 反应 12.0h， 生成 4-哌啶乙醇
  参考文献：
  名称：

  正电子发射断层扫描成像剂18 F-GTP1的稳定前体的实用合成。

  摘要：

  18 F-GTP1是氘化的小分子正电子发射断层扫描（PET）成像剂，用于可视化阿尔茨海默氏病患者的tau缠结。18 F-GTP1的非放射性标记的甲苯磺酸烷基酯前体的第一代合成方法受到产量低，色谱纯化效率低和产品质量可变的困扰。由于这些限制，开发了更强大的第二代路线，并成功地执行了千克规模。LiAlD 4的还原反应引入了双键氘原子，而有效的酰胺化反应则达到了关键的丙烯酰胺偶联伙伴。此外，三环咪唑[1,2- a] pyrimidine核心是通过一种新颖的，会聚的，高选择性的氨基磷酸酯定向环组装而成的。改进的合成过程消除了所有色谱方法，最终实现了高产且可重现的酸促进甲苯磺酸化。

  DOI：

  10.1021/acs.oprd.0c00301
• 作为产物：
  描述：

  4-(2-甲氧基-2-氧代-亚乙基)哌啶-1-羧酸叔丁酯 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 以90 %的产率得到1-N-BOC-4-哌啶乙酸甲酯
  参考文献：
  名称：

  基于卡利拉嗪的多巴胺 D3/D2 受体配体用于治疗可能与情感障碍双重诊断的精神兴奋剂使用障碍

  摘要：

  高选择性多巴胺 D 3受体 (D 3 R) 部分激动剂/拮抗剂已被开发用于治疗精神兴奋剂使用障碍 (PSUD)。然而，由于效力/功效不足或潜在的心脏毒性，尚未进入临床。 Cariprazine 是 FDA 批准的用于治疗精神分裂症和双相情感障碍的药物，是一种高亲和力 D 3 R 部分激动剂 ( K i = 0.22 nM)，其选择性是同源多巴胺 D 2受体 (D 2 R) 的 3.6 倍。我们假设中等 D 3 R/D 2 R 选择性部分激动剂/拮抗剂的化合物可能对 PSUD 的治疗有效。通过系统地修饰母体分子，我们发现了部分激动剂/拮抗剂（在基于生物发光共振能量转移 (BRET) 的测定中测量）具有高 D 3 R 亲和力 ( K i = 0.14–50 nM) 和中等选择性 (<100-折叠 id=63>2 R. 卡利拉嗪和两种先导类似物13a和13e减少大鼠体内可卡因自我给药（FR2；1-10

  DOI：

  10.1021/acs.jmedchem.2c01624
• 作为试剂：
  描述：

  1-叔丁氧羰基-4-哌啶乙酸 、 三甲基硅烷化重氮甲烷 在 1-N-BOC-4-哌啶乙酸甲酯 作用下， 以 甲苯 、 甲醇 为溶剂， 反应 1.0h， 生成 1-N-BOC-4-哌啶乙酸甲酯
  参考文献：
  名称：

  Fused Tricyclic Compounds as novel mTOR inhibitors

  摘要：

  本发明提供了式（I）的融合三环化合物，其中Q，R1，R2，R3和R4如此定义，并且这些融合三环化合物的药学上可接受的盐。这些融合三环化合物在癌症和其他增殖性疾病的治疗中有用。

  公开号：

  US08609675B2

文献信息

• Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
  申请人：Aslanian G. Robert

  公开号：US20070010513A1

  公开（公告）日：2007-01-11

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M 1 and M 3 are CH or N; M 2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH 2 ) q —, —C(═NOR 7 )— or —SO 1-2 —; Z is a bond or optionally substituted alkylene or alkenylene; R 1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula: where ring A is a monoheteroaryl ring; R 1 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.

  揭示了以下化合物的结构式或其药学上可接受的盐，其中： M1和M3为CH或N； M2为CH、CF或N； Y为—C(═O)—、—C(═S)—、—(CH2)q—、—C(═NOR7)—或—SO1-2—；Z为键或可选择地取代的烷基或烯基； R1为H、烷基、烯基，或可选择地取代的环烷基、芳基、杂芳基、杂环烷基或下式的基团： 其中环A为单杂芳基环； R1为可选择地取代的烷基、烯基、芳基、杂芳基、环烷基或杂环烷基；其余变量如规范中所定义；使用这些化合物，单独或与其他药剂结合，治疗过敏引起的气道反应、充血、肥胖、代谢综合征、非酒精性脂肪肝病、肝脂肪变性、非酒精性脂肪性肝炎、肝硬化、肝细胞癌或认知缺陷症状的组合物和治疗方法。
• Constrained compounds as CGRP-receptor antagonists
  申请人：Chaturvedula V. Prasad

  公开号：US20060094707A1

  公开（公告）日：2006-05-04

  The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

  这项发明涵盖了受限的双环和三环CGRP受体拮抗剂，用于识别它们的方法，包含它们的药物组合物，以及它们在治疗偏头痛和其他头痛、神经源性血管舒张、神经源性炎症、热损伤、循环性休克、与绝经期相关的潮红、气道炎症性疾病（如哮喘和慢性阻塞性肺病（COPD））以及其他可以通过CGRP受体拮抗来治疗的疾病的治疗方法。
• CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS
  申请人：Chaturvedula Prasad V.

  公开号：US20070259851A1

  公开（公告）日：2007-11-08

  The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

  本发明包括受约束的双环和三环CGRP受体拮抗剂，识别它们的方法，包含它们的药物组合物，以及它们在治疗偏头痛和其他头痛、神经源性血管扩张、神经性炎症、热损伤、循环性休克、与更年期相关的潮红、气道炎症性疾病（如哮喘和慢性阻塞性肺病（COPD））中的用途，以及其他可以通过CGRP受体拮抗剂治疗的疾病。
• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。
• Oxidative esterification of alcohols by a single-side organically decorated Anderson-type chrome-based catalyst
  作者：Jingjing Wang、Feng Jiang、Chaofu Tao、Han Yu、Laurent Ruhlmann、Yongge Wei

  DOI：10.1039/d1gc00161b

  日期：——

  direct esterification of alcohols with non-noble metal-based catalytic systems faces great challenges. Here, we report a new chrome-based catalyst stabilized by a single pentaerythritol decorated Anderson-type polyoxometalate, [N(C4H9)4]3[CrMo6O18(OH)3C(OCH2)3CH2OH}], which can realize the efficient transformation from alcohols to esters by H2O2 oxidation in good yields and high selectivity without

  醇与基于非贵金属的催化体系直接酯化面临巨大挑战。在这里，我们报告了一种由单季戊四醇修饰的安德森型多金属氧酸盐[N（C 4 H 9）4 ] 3 [CrMo 6 O 18（OH）3 C （OCH 2）3 CH 2 OH}]，可以实现H 2 O 2从醇到酯的高效转化无需额外的有机配体，即可以高收率和高选择性进行氧化。该系统可耐受各种功能不同的醇，包括某些天然产物和医药中间体。铬基催化剂可以循环使用几次，并且仍保持原始配置和催化活性。我们还提出了合理的催化机制，并证明了其在工业上的应用潜力。